The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC).
Dirk Strumberg
No relevant relationships to disclose
Beate Schultheis
No relevant relationships to disclose
Matthias Philip Ebert
No relevant relationships to disclose
A. Kerkhoff
No relevant relationships to disclose
Ralf Dieter Hofheinz
No relevant relationships to disclose
Dirk M. Behringer
No relevant relationships to disclose
Wolfgang E. Schmidt
No relevant relationships to disclose
Erdem Goker
No relevant relationships to disclose
Sara De Dosso
No relevant relationships to disclose
Michael Kneba
No relevant relationships to disclose
Suayib Yalcin
No relevant relationships to disclose
Friedrich Overkamp
No relevant relationships to disclose
Frank Schlegel
No relevant relationships to disclose
M. Dommach
No relevant relationships to disclose
Robert Rohrberg
No relevant relationships to disclose
Tilman Steinmetz
No relevant relationships to disclose
Dirk Reuter
Employment or Leadership Position - Oncoscience
Ferdinand Bach
Employment or Leadership Position - Oncoscience